MedTrace Logo

Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma

NCT01863108 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-08-13

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of multiple sub-cutaneous injections of GeniusVac-Mel4, a dendritic cell-based cancer vaccine, in patients with melanoma. The secondary objectives are to determine immune response and clinical efficacy of such injections in patients with melanoma.

Conditions

  • Melanoma
  • Tumor Vaccines
  • Effects of Immunotherapy

Interventions

BIOLOGICAL

GeniusVac-Mel4

Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma

Sponsors & Collaborators

  • Etablissement Français du Sang

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Université Joseph Fourier

    collaborator OTHER

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Joel Plumas, PhD · Etablissement Français du Sang/Grenoble University/ INSERM U823

  • Julie Charles, MD, PhD · University Hospital, Grenoble

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2017-03-23
Completion
2017-03-23

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01863108 on ClinicalTrials.gov